Vergabebekanntmachung nach § 30 UVgO:
- Name und Anschrift des Auftraggebers und dessen Beschaffungsstelle: „Institut für Medizinische Mikrobiologie, Immunologie und Hygiene; Technische Universität München; Trogerstr. 30; 81675 München“
- Name des beauftragten Unternehmens: „Sigma-Aldrich Chemie GmbH.“
- Verfahrensart: „Verhandlungsvergabe ohne Teilnahmewettbewerb“
- Art und Umfang der Leistung: „Bezug von 200 Flasche FCS (Fetales Kälberserum) nach umfangreicher Vergleichstestung “
- Zeitraum der Leistungserbringung: „Dezember 2024“
________________________________________________________________________________________________________________________
Game-changing research collaboration starts:
Vax2Muc will pave the way for next-generation vaccines against gastrointestinal mucosal pathogens
The constant rise in antimicrobial resistance (AMR) has a major impact on global public health, urgently requiring novel strategies to prevent and treat bacterial infections. The development of effective vaccines represents an attractive cost-effective alternative to novel antibiotics and would be a game changer for patients. For many bacterial infections, especially those occurring on mucosal sites, no effective vaccines exist. Helicobacter pylori (H. pylori), a pathogen residing in the stomach, is the cause of the most common chronic bacterial infection, affecting half of the world´s population, with a high risk to progress into gastric cancer...
____________________________________________________________________________________________________________________________
Lymphocyte Engineering for Therapeutic Synthetic Immunity
Adoptive T cell therapy has advanced to become a distinguished and rapidly evolving translational research field in modern medicine....
